ArticleNature cancer2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02541604 (An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science.Journal of clinical pharmacology · 2026Review
- Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.Scientific reports · 2026Article
- Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications.Discover oncology · 2025Review
- Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi.Blood global hematology · 2025Article
- B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors.Cancer metastasis reviews · 2025Review
- Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond.Molecular cancer · 2024Review
- Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer.Journal of translational medicine · 2024Article
- Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress.Cold Spring Harbor perspectives in medicine · 2024Review
- Harnessing immune checkpoint trial data in pediatric cancer.Nature cancer · 2023Article
- Heterogeneity of tertiary lymphoid structures in cancer.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 8 institutions in 5 countries.
Funding
Abstract
We report herein an exploratory biomarker analysis of refractory tumors collected from pediatric patients before atezolizumab therapy (iMATRIX-atezolizumab, NCT02541604 ). Elevated levels of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.